For fiscal 2026, Knight expects to generate between $490 million to $510 million in revenues and adjusted EBITDA1 to be approximately 15% of revenues.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year
- Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
- Knight announces approval of additional MINJUVI indication in Brazil
- KHTRF Upcoming Earnings Report: What to Expect?
- Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil